Voorberg J, de Laaf R T, Koster P M, van Mourik J A
Department of Blood Coagulation, The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Biochem J. 1996 Sep 15;318 ( Pt 3)(Pt 3):931-7. doi: 10.1042/bj3180931.
Substitution of Arg2307 by Gln in factor VIII has been found to be associated with mild to moderate haemophilia A [Gitschier, Wood, Shuman and Lawn (1986) Science 232, 1415-1416]. We have introduced this particular point mutation into a B-domain-deleted factor VIII cDNA and expressed the modified cDNA in C127 cells. Cells expressing the resulting protein, termed des-(868-1562)-factor VIII-R2307Q, were compared with those expressing the previously characterized des-(868-1562)-factor VIII. No immunoreactive material could be detected in the conditioned medium of cells transfected with des-(868-1562)-factor VIII-R2307Q cDNA using assays specific for the factor VIII light chain and the factor VIII heavy chain. Analysis of metabolically labelled cells transfected with des-(868-1562)-factor VIII-R2307Q cDNA revealed that this mutant protein is synthesized at a level similar to des-(868-1562)-factor VIII. In contrast to des-(868-1562)-factor VIII, metabolically labelled des-(868-1562)-factor VIII-R2307Q was not encountered in the conditioned medium of the transfected cells, indicating that the mutant protein is not secreted from the cell. Inspection of the intracellular localization of the two proteins in the cell employing morphological analysis, endoglycosidase H and experiments with inhibitors of glucosidases I and II was consistent with localization of des-(868-1562)-factor VIII and des-(868-1562)-factor VIII-R2307Q in the endoplasmic reticulum. Taken together, our data indicate that the Arg2307-->Gln mutation results in aberrant intracellular trafficking of factor VIII, which may explain the low levels of factor VIII antigen in the plasma of haemophilia A patients that carry this particular point mutation.
已发现因子VIII中第2307位的精氨酸被谷氨酰胺取代与轻度至中度A型血友病相关[吉施切尔、伍德、舒曼和劳恩(1986年),《科学》232卷,第1415 - 1416页]。我们已将这个特定的点突变引入缺失B结构域的因子VIII cDNA中,并在C127细胞中表达了修饰后的cDNA。将表达所得蛋白质(称为缺失(868 - 1562)-因子VIII - R2307Q)的细胞与表达先前已鉴定的缺失(868 - 1562)-因子VIII的细胞进行比较。使用针对因子VIII轻链和因子VIII重链的特异性检测方法,在转染了缺失(868 - 1562)-因子VIII - R2307Q cDNA的细胞的条件培养基中未检测到免疫反应性物质。对转染了缺失(868 - 1562)-因子VIII - R2307Q cDNA的代谢标记细胞的分析表明,这种突变蛋白的合成水平与缺失(868 - 1562)-因子VIII相似。与缺失(868 - 1562)-因子VIII不同,在转染细胞的条件培养基中未发现代谢标记的缺失(868 - 1562)-因子VIII - R2307Q,这表明突变蛋白未从细胞中分泌出来。采用形态学分析、内切糖苷酶H以及使用葡糖苷酶I和II抑制剂的实验对细胞中这两种蛋白质的细胞内定位进行检查,结果与缺失(868 - 1562)-因子VIII和缺失(868 - 1562)-因子VIII - R2307Q定位于内质网一致。综上所述,我们的数据表明,精氨酸2307→谷氨酰胺突变导致因子VIII的细胞内运输异常,这可能解释了携带这种特定点突变的A型血友病患者血浆中因子VIII抗原水平较低的原因。